Skip to main content
Premium Trial:

Request an Annual Quote

Immunovia Raises $37.1M

NEW YORK (GenomeWeb) – Swedish molecular diagnostics company Immunovia today announced it has raised SEK 324 million ($37.1 million) in gross proceeds in a directed share issue.

The firm issued almost 2.2 million new shares at a subscription price of SEK 150 per share. Proceeds will be directed at acceleration of Immunovia's planned launch of its Immray PanCan-d assay and to build a US sales staff and operation. The company announced a year ago the creation of a US subsidiary in Boston to house commercialization operations and a CLIA reference laboratory.

Proceeds will also be used to fund marketing and sales efforts, and continued product development, Immunovia said.

Its flagship product is the Immray PanCan-d assay. The antibody-based microarray measures about 25 biomarkers associated with pancreatic cancer, allowing clinicians to detect stage I and II pancreatic cancers when they are still resectable. 

Immunovia launched in late 2016 its PanFAM-1 clinical validation study for applying the assay in familial pancreatic cancer. The study aims to look at more than 1,000 individuals over three years across sites in Sweden, the US, and Europe. Sites participating in it so far include Mount Sinai, Linköping University Hospital, NYU School of Medicine, and others.

The company has also initiated another study to diagnose early-stage pancreatic cancer in new onset diabetes patients.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.